Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of BMS-986465 in Healthy Participants
NCT06144697Phase 1Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-986465 in multiple sclerosis (MS) and neuroinflammatory disorders (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of adverse events (AEs) up to 28 days, Incidence of serious adverse events (SAEs) up to 28 days and 4 more. Started Jan 2024; status: terminated.
02
Drugs
BMS-986465
03
Conditions
multiple sclerosis (MS)neuroinflammatory disorders
Beyond the preview
Go deeper on NCT06144697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06144697.